A groundbreaking accomplishment has emerged in the realm of Parkinson's disease diagnosis, as scientists have devised a blood test capable of detecting the condition. This innovation holds the potential to enable the identification of Parkinson's disease at an earlier stage, offering prospects for intervention before the deterioration of the nervous system progresses.
The development of a blood-based diagnostic test constitutes a significant stride in addressing Parkinson's disease, a pervasive ailment affecting 10 million individuals globally and ranking as the second most common neurodegenerative disorder following Alzheimer's.
Typically, the diagnosis of Parkinson's disease relies heavily on clinical symptoms that manifest once substantial neurological impairment has already transpired. Dr. Laurie Sanders, a senior author of the study and an associate professor in the Duke School of Medicine's Neurology and Pathology departments, along with her colleagues, seeks to revolutionize this paradigm. Their pioneering blood test could enable swifter disease diagnosis and initiation of therapeutic measures. Furthermore, it promises to precisely identify eligible candidates for drug trials, catalyzing the advancement of improved therapies and potentially curative interventions.
Central to this diagnostic tool is a biomarker rooted in mitochondrial DNA damage. Mitochondria, the energy-producing centers within cells, harbor their own distinct DNA. Earlier research has linked mitochondrial DNA damage to an elevated risk of Parkinson's disease. Building on their prior work revealing the accumulation of such damage in the brain tissue of deceased Parkinson's patients, the Duke team harnessed polymerase chain reaction (PCR) technology to devise an assay that effectively quantifies heightened levels of mitochondrial DNA damage in blood cells extracted from individuals with Parkinson's disease.
With a forward-looking perspective, Dr. Sanders underscores the test's dual potential: not only could it diagnose Parkinson's disease, but it might also be able to identify pharmaceutical agents capable of ameliorating or arresting mitochondrial DNA damage and the disease's progression. By advancing research into these dimensions, Sanders envisions an era where novel, efficacious treatments can be advanced to address the root causes of Parkinson's disease, transcending mere symptom management. The research team's next steps include the extended assessment of the assay using samples from individuals in the earliest phases of the disease, potentially facilitating interventions even before symptomatic manifestation.
Source: Avery, Sarah. DukeHealth. "New Blood Test Detects a Key Indicator of Parkinson’s Disease". https://corporate.dukehealth.org/news/new-blood-test-detects-key-indicator-parkinsons-disease, 30 Aug, 2023. [Date accessed: 31 Aug, 2023].
Edited by: Pulkit Pincha
תגובות